Diclazepam
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Diclazepam (2-chlorodiazepam) is a synthetic depressant of the benzodiazepine class. It is a close structural relative of diazepam (Valium), distinguished by a longer duration and heavier sedative character.[1] It amplifies the brain's main inhibitory signaling system — GABA — producing broad suppression of neural activity.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, alcohol, barbiturates +3 morebenzodiazepines, alcohol, barbiturates, zolpidem, zopiclone, zaleplon show less
Synthesized by Leo Sternbach around 1960 as part of a systematic benzodiazepine development program, it was catalogued internally but never brought to clinical development.[4][2] It resurfaced in 2012 as one of the first designer benzodiazepines to reach online research chemical markets.[4] Diclazepam is now permanently scheduled in the United States, the European Union, and the United Kingdom.
Subjective effects include sedation, anxiety relief, muscle relaxation, and thought deceleration. The experience is defined by gradual, enveloping calm — anxiety recedes first, creating a window of functional relief before heavier sedation sets in. Amnesia for events during the experience, disinhibition, and a false sense of being sober while significantly impaired are characteristic unwanted effects.
Diclazepam produces physical dependence with repeated use, and active metabolites accumulate in the body for days, extending sedation far beyond perceived sobriety.[5][4] All documented fatalities involve combinations with opioids or other depressants — the compound amplifies respiratory depression when combined, and this is the dominant risk mode.[6] Understanding rests on a single self-experiment and forensic case reports; no controlled human studies have been conducted.[1]
History[edit]
Discovery
Leo Sternbach synthesized diclazepam at Hoffmann-La Roche around 1960, as part of the program that also produced diazepam and chlordiazepoxide.[4][2] Catalogued internally as Ro 5-3448, it was patented but never brought to clinical development — Roche published no pharmacological data, and no pharmaceutical product was ever marketed.[4][2]
Emergence as a designer benzodiazepine
Diclazepam appeared on online research chemical markets in 2012, among the first designer benzodiazepines to reach widespread availability.[4][2][7] The first scientific characterization came in 2014, when Moosmann, Bisel, and Auwärter published analytical data alongside the only human pharmacokinetic study — a single-person self-experiment.[4]
Regulatory response
Regulatory action followed as diclazepam appeared in forensic casework and fatality reports. Germany scheduled it in November 2015, the UK in June 2017, the EU in March 2024,[8] and the United States permanently placed it in Schedule I in April 2026.[9]
The name diclazepam follows standard benzodiazepine naming conventions: the di- prefix references two chlorine atoms, while -azepam denotes the seven-membered ring shared by the classical benzodiazepine family. The alternate names 2-chlorodiazepam and chlorodiazepam describe its structural relationship to diazepam.
Chemistry[edit]
Structure
Diclazepam belongs to the 1,4-benzodiazepin-2-one family — the core scaffold shared by diazepam, nitrazepam, clonazepam, and most classical pharmaceutical benzodiazepines. It is the 2′-chloro structural analog of diazepam: structurally identical except for an additional chlorine on the pendant phenyl ring, a single halogen that produces measurably different pharmacological activity.[1] Its molecular formula is C₁₆H₁₂Cl₂N₂O (molecular weight 319.2 g/mol).
Stereochemistry & Physical properties
Diclazepam has no chirality centers and exists as a single constitutional isomer. A forensically relevant complication: its positional isomer 4′-chlorodiazepam shares nearly identical mass spectral fragmentation patterns, requiring laboratory chromatographic separation for unambiguous identification.[11] It presents as a white crystalline powder with physicochemical properties that predict efficient oral absorption and ready crossing of biological membranes.[12]
Pharmacology[edit]
Mechanism of action
Diclazepam amplifies GABA receptors — the brain's main system for quieting neural activity.[2][3] It does not activate them directly; instead, it makes them respond more strongly when the brain's own GABA is present, increasing the flow of inhibitory signals across the central nervous system. No direct binding measurements have been published; computational modeling predicts potent activity at the benzodiazepine binding site consistent with its structural features.[13][14][6]
Pharmacokinetics
Diclazepam is taken orally. The body eliminates it slowly — the half-life is approximately 42–46 hours, meaning half the compound remains in the blood nearly two days after a single dose.[4][6] Oral absorption is expected to be efficient based on the compound's physical properties.[12]
The body converts diclazepam into three pharmacologically active breakdown products: delorazepam (the primary metabolite, itself a long-acting benzodiazepine), lorazepam, and lormetazepam.[4] Delorazepam persisted in blood for up to 10 days after a single dose; lorazepam appeared in urine for up to 19 days.[4]
Neuroscience[edit]
Where it acts
Diclazepam's effects arise from amplified inhibitory signaling throughout the brain. In the thalamus, this reduces sensory input and promotes sedation. In the amygdala and hippocampus, it dampens fear responses and suppresses anxiety[10] — and hippocampal inhibition also blocks new memory formation, causing anterograde amnesia that can persist long after the perceived experience has ended.
Why it matters
Diclazepam also affects the brain's reward circuitry. By quieting inhibitory neurons in a key dopamine pathway, it allows dopamine to flow more freely.[15] Animal studies confirm this reinforcing potential, though the pull appears to come from relief of distress rather than pleasure-seeking.[5]
This pattern — wanting the absence of anxiety rather than the presence of euphoria — may explain why self-medication is diclazepam's dominant documented use pattern.[10]
Key unknowns include whether diclazepam preferentially engages specific GABA receptor subtypes — which would determine the balance of sedative, anxiety-relieving, and amnestic effects. Repeated use drives receptor changes that underlie both tolerance and the severity of withdrawal.
Subjective Effects[edit]
The diclazepam experience is defined by what it removes. Anxiety dissolves first, followed by progressive sedation and cognitive slowing — a gradual, enveloping calm rather than a sharp intoxication. At lower doses this creates a functional window of relief; as the dose rises, sedation deepens and behavioral control narrows.
Compared to diazepam, the experience is qualitatively similar but longer-lasting and more sedating at equivalent doses. Relative to shorter-acting designer benzodiazepines like etizolam, the onset is slower and the peak less sharply defined — characteristics that account for its documented use as a tool for sustained anxiety suppression and withdrawal management.[10]
Effect Grid
Clear anxiety suppression and moderate sedation at 1–3 mg. The anxiolytic effect is now unambiguous — worry and tension dissolve noticeably. Thought deceleration becomes apparent: information processing slows, and concentration narrows. Emotional suppression flattens both positive and negative affect. Some anterograde amnesia is possible at the upper end of this range.
Muscle relaxation becomes pronounced. Motor control impairment is mild but measurable — fine motor tasks and balance are affected. Sedation may produce drowsiness, especially in the evening. Dizziness is possible.
Disinhibition and delusions of sobriety are significant risks at common doses. Users may believe themselves fully functional while exhibiting slurred speech, impaired judgment, and ataxia visible to others. The 8–12 hour subjective duration understates true pharmacological exposure due to active metabolites persisting for days.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity suppression · Visual haze / noise · Visual processing suppression
Bodily heaviness · Dizziness · Body high · Nystagmus (eye wobbles) · Nausea
Nausea
Cognitive fatigue · Focus suppression · Information processing suppression · Memory suppression · Memory fragmentation · Thought disorganization · Confusion · Language suppression · Motivation suppression · Suggestibility enhancement · Compulsive redosing urge · Amnesia · Delirium
Memory suppression · Memory fragmentation · Thought disorganization · Confusion · Language suppression · Motivation suppression · Compulsive redosing urge · Amnesia · Delirium
Dysphoria
Depersonalization · Derealization · Cognitive disconnection
Timeline
First perceptible anxiolysis emerges as a subtle loosening of tension. Physical awareness is minimal — slight warmth or relaxation may be noticed.
Anxiolysis deepens and sedation begins to establish. Muscle relaxation becomes noticeable. Thought deceleration starts — the mind quiets progressively.
Full sedation, anxiolysis, and muscle relaxation. Cognitive slowing and amnesia risk are maximal. Disinhibition and delusions of sobriety are prominent at higher doses.
Gradual reduction in perceived sedation. Functional
⚠ impairment persists beyond subjective awareness — the mismatch between felt sobriety and actual impairment drives compulsive redosing risk.
Residual effects from active metabolites produce subtle cognitive impairment and muscle relaxation lasting 12–48 hours. Users may not perceive impairment.
⚠ Do not drive or operate machinery for at least 24 hours after ingestion — active metabolites produce residual impairment that may not be subjectively apparent.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- benzodiazepines · alcohol · barbiturates
Toxicity
Acute toxicity
No lethal dose data have been published for diclazepam in any species. safety citation needed One clinical case report of diclazepam overdose exists,[16] but no systematic toxicological profile has been established.
Polydrug fatalities
All documented fatalities involving diclazepam occur in polydrug contexts — typically combinations with opioids or other CNS depressants.[6] Documented deaths include a case involving the synthetic opioid U-47700[17] and a case of positional asphyxia during designer benzodiazepine–stimulant intoxication.[18]
Metabolite accumulation
All three primary metabolites — delorazepam, lorazepam, and lormetazepam — are pharmacologically active.[4] Delorazepam's half-life may exceed 100 hours, building cumulative sedation across doses far beyond what the user perceives. Lorazepam remains detectable in urine up to 19 days after a single dose.[4]
Drug-facilitated crime
The strong amnestic and sedative effects, combined with poor detectability on standard immunoassay panels, make diclazepam relevant in drug-facilitated sexual assault contexts.[19][20]
Psychological risks
No controlled studies of diclazepam's psychological effects have been conducted.
Acute risks include anterograde amnesia, disinhibition leading to uncharacteristic or dangerous behavior, delusions of sobriety (the false belief of being functionally sober while significantly impaired), and paradoxical aggression.
Chronic risks include cognitive impairment, emotional suppression, and psychological dependence. The long half-life and active metabolite cascade can produce cumulative impairment the user does not perceive.
Withdrawal can produce rebound effect anxiety exceeding pre-use baseline, insomnia, depersonalization, and in severe cases psychosis or suicidal ideation — established at the benzodiazepine class level.[21]
Tolerance and dependence
Tolerance develops through downregulation and changes in receptor subunit composition in the brain.[15] Sedative tolerance typically emerges earlier than anxiolytic tolerance. No diclazepam-specific tolerance timeline data have been published. safety citation needed
Physical and psychological dependence form with repeated use, confirmed in rodent self-administration studies.[5] Standard urine immunoassays may fail to detect diclazepam, complicating clinical assessment of dependence.[22][23]
A documented paradox: 22.6% of user forum posts identified managing benzodiazepine withdrawal as a primary motivation for diclazepam use.[10] Self-tapering with unregulated diclazepam substitutes one unknown variable for another — tablet content can range from 0.59 to 1.39 mg per declared 1 mg unit.[10]
Benzodiazepine withdrawal can be life-threatening. Seizures are the most serious acute complication. Medical options include supervised outpatient taper, inpatient stabilization, and adjunctive therapy.[21]
Cross-tolerance exists with all GABAergic substances: other benzodiazepines, alcohol, barbiturates, and Z-drugs.
Drug interactions
The primary risk is additive or synergistic CNS and respiratory depression when combined with other depressants. All published diclazepam-associated fatalities involve polydrug combinations.
Opioids carry the highest documented risk. Diclazepam–opioid combinations produce both direct additive respiratory depression and metabolic interactions that compound toxicity.[24] A fatal case involving diclazepam and the synthetic opioid U-47700 is documented.[17]
Alcohol produces additive GABA potentiation with elevated overdose risk. Other benzodiazepines produce cumulative depression; diclazepam's metabolite delorazepam adds to the total benzodiazepine load. Barbiturates and Z-drugs carry additive respiratory depression risk.
Flumazenil (a benzodiazepine antagonist) reverses diclazepam-induced sedation,[25][6] but its shorter half-life means sedation may return after 1–2 hours, potentially requiring repeated doses.[26] In physically dependent users, flumazenil can trigger withdrawal seizures.
Contraindications
No substance-specific contraindication studies have been conducted. The following apply by benzodiazepine class pharmacology:
Absolute contraindications:
- Concurrent opioid use without medical supervision — documented synergistic respiratory depression with fatality risk[24][17]
- Severe respiratory insufficiency — respiratory depression compounds existing ventilatory compromise
- Acute alcohol intoxication — additive CNS depression with aspiration and respiratory arrest risk
- Known hypersensitivity to benzodiazepines
Relative contraindications:
- Liver impairment — impaired clearance would prolong and intensify effects inferred
- History of substance use disorder — reinforcing properties confirmed;[5] high self-medication use documented[10]
- Pregnancy — benzodiazepines carry teratogenic and neonatal withdrawal risk inferred
- Myasthenia gravis — muscle relaxation may worsen neuromuscular dysfunction
- Sleep apnea — respiratory depression worsens obstructive and central apneic events
Harm Reduction[edit]
Forms & Identification
Tablet content varies significantly — UK market analysis found actual content ranging from 0.59 to 1.39 mg per declared 1 mg unit, a variance of more than double.[10] No reagent test can reliably distinguish diclazepam from other designer benzodiazepines; laboratory-grade analytical techniques are required for confirmatory identification.
Powder forms present the highest dosing risk. At active doses below 2 mg, a standard scale cannot measure accurately. A precision milligram balance (0.001 g resolution) is the minimum tool for direct measurement; volumetric dosing — dissolving a known weight in a measured volume of solvent — is more reliable.
Guidelines
- Test substance identity when possible. Reagent kits cannot confirm diclazepam specifically but can rule out some substitutions.
- Start at the lowest available dose and wait at least 3 hours before considering redosing — the slow onset and long duration make premature redosing a primary risk.
- Use volumetric dosing for powder forms. Dissolve a known weight in a measured volume of propylene glycol or another suitable solvent.
- Avoid combining with any other depressant — including alcohol, opioids, other benzodiazepines, or sleep medications.
- Inform a trusted person of the substance, dose, and timing.
- Secure valuables, lock away car keys, and remove access to additional substances before dosing — benzodiazepine disinhibition and amnesia create conditions for compulsive redosing.
Set & Setting
Diclazepam's extended duration — 8–12 hours of perceived effects, with metabolite activity lasting days — requires planning for sustained impairment. Activities requiring coordination, judgment, or memory should be avoided for at least 24 hours after dosing, and longer after repeated use.
The delusions of sobriety effect means users frequently underestimate impairment. A sober companion who knows the timing and dose provides an external check.
Aftercare & integration. Residual impairment from diclazepam and its active metabolites persists well beyond the period of perceived effects. Cognitive slowing, memory gaps, and impaired coordination may continue for 24–72 hours after a single dose.
Allow full recovery before driving, making significant decisions, or returning to work. Prioritize sleep, hydration, and regular meals during the recovery window. If amnesia occurred, reconstruct the timeline with a sober companion to identify any actions or communications made during the amnestic period. If diclazepam was used daily for more than a week, do not stop abruptly — abrupt cessation carries seizure risk. Seek medical guidance for tapering.
Recovery & Support
Benzodiazepine dependence is a medical condition that responds to structured treatment. Recovery typically involves a gradual dose taper under medical supervision — abrupt cessation is dangerous and medically contraindicated after sustained use.
Resources for support include:
- Medical taper: A physician experienced in benzodiazepine withdrawal can design a tapering schedule. This is the safest path and the first step.
- SAMHSA National Helpline: 1-800-662-4357 (US) — free, confidential, 24/7 referral and information.
- Benzodiazepine Information Coalition: benzoinfo.com — peer support, medical provider directory, and tapering resources.
- BenzoBuddies: benzobuddies.org — peer community for people tapering or in recovery.
Self-tapering with unregulated diclazepam substitutes one uncontrolled variable for another. Medical supervision provides dosing precision and seizure monitoring that self-management cannot replicate.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow or shallow breathing, blue-tinged lips or fingertips, unresponsiveness to voice or pain, vomiting while sedated, or seizures. These signs require immediate help — not observation.
Immediate steps:
- 1. Call emergency services.
- 2. Place the person in the recovery position (on their side) to prevent aspiration if they are breathing.
- 3. Do not induce vomiting.
- 4. Do not leave the person alone.
- 5. Monitor breathing continuously until help arrives.
What to tell the dispatcher: Name the substance (diclazepam or "a designer benzodiazepine"), the approximate dose and time taken, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution.
Reversal: Flumazenil can reverse benzodiazepine sedation but is a hospital-administered drug. Its shorter half-life means sedation may return after 1–2 hours. In dependent users, flumazenil can trigger seizures.
Legal Status[edit]
Diclazepam was progressively scheduled across major jurisdictions as it appeared in forensic casework, poison control reports, and fatalities.
In the United States, diclazepam was temporarily placed in Schedule I effective July 2023.[27] Permanent Schedule I placement took effect on April 1, 2026.[9] The European Union adopted control measures via Council Decision (EU) 2024/832 on March 4, 2024.[8]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Permanently scheduled effective April 1, 2026; previously temporary Schedule I from July 2023[9] |
| United Kingdom | Class C, Schedule 2 (Misuse of Drugs Act 1971) | Controlled since June 2017; regulations amended 2024 |
| Germany | Anlage II (BtMG) | Scheduled November 21, 2015; license required for manufacture, possession, import, export, sale |
| European Union | EU-wide control measures | Council Decision (EU) 2024/832, March 4, 2024[8] |
| Canada | Schedule IV (CDSA) | All benzodiazepines scheduled by class |
| Sweden | Nationally controlled | Controlled as part of NPS benzodiazepine scheduling; STRIDA monitoring data available[28] |
| Australia | Status not confirmed | Insufficient data from available sources citation needed |
Legal status changes frequently. This information reflects known status as of 2026 and is not legal advice. Verify current status in any relevant jurisdiction before taking action.
references
- [1] ^abcMoustafa RE, Tarbah F, Saeed HS, Sharif SI (2021) Designer benzodiazepines versus prescription benzodiazepines: can structural relation predict the next step? — Critical Reviews in Toxicology doi:10.1080/10408444.2021.1907303
- [2]
- [3] ^abLuethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects — Archives of Toxicology doi:10.1007/s00204-020-02693-7
- [4]
- [5] ^abcdLee W, Lee JW, Kim S, Kim JM, Youn DH, Park SH, Kwon CH, Choi SO (2024) Discriminative stimulus and reinforcing effects of diclazepam in rodents. — Pharmacology, Biochemistry, and Behavior doi:10.1016/j.pbb.2023.173687
- [6]